Project description DEENESFRITPL Disruptive implants regenerate bone after surgery Every year 1.6 million people in Europe require orthopaedic surgery after bone, ligament or tendon injuries. Current implant materials produce imperfect healing outcomes but NORAKER's technology was adapted for knee ligament regeneration and validated for potential interventions in bone, tendon and ligament injuries. NORAKER's bio-absorbable composite implants can recreate native-like bone structure with no inflammation or pain and very low re-operational risk. The EU-funded REBOOT project will introduce and validate these new first-in-class implants to achieve full healing after orthopaedic surgeries. This involves scale-up of the bio-composite implant for industrial production, supporting the transition towards a truly regenerative orthopaedic surgery. Show the project objective Hide the project objective Objective NORAKER develops first-in-class implants for regenerative orthopaedic surgery to offer full healing to patients suffering from a bone, ligament or tendon injury. With project REBOOT, NORAKER will create the market of bone regeneration surgery.Each year in Europe, 1,6 million people require orthopaedic surgery after a bone, ligament or tendon injury, with many more cases expected as population ages. The current implants (made of metallic or bioresorbable materials) show imperfect healing outcomes, leaving millions of patients with fragile bones and poor quality of life (with 30% of inflammation, 20% of revision surgery and millions suffering from chronic pain and musculoskeletal disorders, MSDs). It weights billions of follow-up costs on the community.Enter NORAKER’s biocomposite surgical implants, made of bioactive glass – a revolutionary ceramic – mixed with a synthetic polymer, both bioabsorbable. This technology shows disruptive regeneration action: it can recreate up to 100% of the native-like functional bone structure with no inflammation, no abnormal pain, no MSD and a very low re-operation rate (4%). Today this patented technology is adapted to knee cruciate ligaments regeneration (with a world-first biocomposite screw marketed in 2015).In a SME Instrument Phase 1 project (2018), NORAKER has validated the feasibility of a new biocomposite formula with broader perspectives of regeneration for tendon, ligament and bone injuries.The Phase 2 project will do the industrial scale-up of this biocomposite and launch the industrial production of the first range of implants for the bone trauma market. Their adoption will support the transition toward regenerative orthopaedic surgery and break the spiral of pain and MSDs, which too many patients are experiencing these days.With this disruptive offer, NORAKER will become a scale-up operating worldwide, with a large manufacturing capablity, international sales and turnover multiplied by 15 in five years. Fields of science medical and health sciencesclinical medicinesurgeryengineering and technologymaterials engineeringcompositesbiocompositesnatural scienceschemical sciencespolymer sciencesmedical and health sciencesclinical medicineorthopaedicsmedical and health sciencesmedical biotechnologyimplants Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator NORAKER Net EU contribution € 2 481 500,00 Address 60 avenue rockefeller 69008 Lyon France See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 063 500,00
